Cooperative Agreement NU51CK000318

This Project Grant award for $665,171.00, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to improve outcomes for individuals with HIV-associated opportunistic infections like cryptococcal and TB meningitis. The key objectives are to: 1) define CSF drug concentrations or AUC/MIC ratios that predict fungal clearance, 2) determine the relationship between...

This Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 - International Research and Research Training) is focused on determining the prevalence and risk factors for persistent neurological deficits after cryptococcal meningitis among survivors in Uganda. The $174,687 award to the Infectious Diseases Institute LIMITED (IDI) in Kampala, Uganda will fund a study to: 1) measure the prevalence of sustained neurocognitive impairment at 1 year...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $215,860 to the Regents of the University of Minnesota to support a mid-career investigator's research focused on improving the diagnosis, treatment, and prevention of neuro-infections, particularly HIV-related cryptococcal and tuberculosis meningitis. The key products and services to be delivered through this 5-year...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,326,630 to Duke University to conduct research on improving treatment strategies for talaromycosis, a deadly fungal infection prevalent in Southeast Asia. The key objectives are to: 1) Determine if a single high-dose of liposomal amphotericin B (LAMB) is superior to the standard 14-day course of amphotericin B...

This Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 - International Research and Research Training) will provide $108,916 to Kamuzu University of Health Sciences in Malawi to characterize the pharmacokinetic and safety profiles of the antimalarial drugs artemether-lumefantrine plus amodiaquine (ALAQ) in two key target populations: children with severe acute malnutrition and adults living with HIV on dolutegravir-based antiretroviral...

This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...

This $196,881 Project Grant was awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) to adapt and pilot test an intervention to reduce alcohol use and improve HIV care outcomes among men living with HIV who have serodiscordant pregnant partners in Uganda. The overarching goal is to adapt the KISOBOKA intervention, which utilizes motivational interviewing and behavioral economics techniques, for use with this target...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $702,000 to support a 3-year project aimed at optimizing the implementation of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention. The key objectives are to: 1) Identify barriers and facilitators to LAI-PrEP implementation, 2) Determine optimal implementation strategies in partnership with...

This $582,959 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to integrate a "Universal Test-and-Connect" (UTC) strategy for HIV prevention and treatment services into two high-volume emergency department (ED) settings in Cape Town, South Africa. The 3-year project, running from September 2024 to September 2027, has three key objectives: Integrate HIV assessment into...